Plain-English translation of NCT06014190 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Ovarian Cancer research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This is a Phase 2 trial testing a new injectable medication called for people with ovarian cancer, endometrial cancer, or certain other advanced cancers that have come back or stopped responding to earlier treatments. The study will enroll about 460 people across multiple sites and will happen in two stages: first, researchers will test different doses and groups of patients to learn how well the medication works and what side effects occur; then, they will study the most promising dose in a larger group to confirm its benefits.
Current treatments for advanced ovarian and endometrial cancers don't work for everyone, and many patients' cancers become resistant to platinum-based chemotherapy or return after treatment. This medication targets a specific protein on cancer cells (called B7-H4) that may help the immune system fight cancer more effectively.
You likely qualify if…
You likely don't qualify if…
You will receive as an injection at a hospital or clinic. The study has two phases: in Phase 2a, researchers will test different doses in different patient groups to find the best dose and learn about side effects; in Phase 2b, more patients will receive the medication at the dose that works best. You will have regular clinic visits for physical exams, blood tests, and imaging scans to see how well the treatment is working and to monitor for side effects. The study involves a newly obtained tumor biopsy or recent archived tumor tissue to help personalize treatment.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China